Vetoquinol SA (EPA:VETO)

Market Cap	861.08M
Revenue (ttm)	539.20M
Net Income (ttm)	58.69M
Shares Out	11.80M
EPS (ttm)	4.98
PE Ratio	14.67
Forward PE	14.31
Dividend	0.89 (1.22%)
Ex-Dividend Date	Jun 4, 2025

Volume	4,632
Average Volume	2,642
Open	73.60
Previous Close	73.00
Day's Range	72.80 - 73.60
52-Week Range	63.60 - 102.80
Beta	0.78
RSI	54.24
Earnings Date	Sep 11, 2025

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, pigs, dogs, and cats. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of S...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1933
• Employees: 2,501
• Stock Exchange: Euronext Paris
• Ticker Symbol: VETO

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.69 million, an increase of 5.62%.